Baker Brothers Advisors - BIOMARIN PHARMACEUTICAL INC ownership

BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 51 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of BIOMARIN PHARMACEUTICAL INC
ValueSharesWeighting
Q3 2021$4,611,000
-70.4%
4,500,000
-70.0%
0.02%
-70.6%
Q2 2021$15,566,000
+1.7%
15,000,0000.0%0.07%
+3.0%
Q1 2021$15,299,000
-4.6%
15,000,0000.0%0.07%
+10.0%
Q4 2020$16,033,000
+2.4%
15,000,0000.0%0.06%
-4.8%
Q3 2020$15,650,000
-14.7%
15,000,0000.0%0.06%
-22.2%
Q2 2020$18,340,000
+17.7%
15,000,0000.0%0.08%
-15.6%
Q1 2020$15,576,000
-1.7%
15,000,0000.0%0.10%
+14.3%
Q4 2019$15,841,000
+7.6%
15,000,0000.0%0.08%
-16.0%
Q3 2019$14,722,000
-5.4%
15,000,0000.0%0.10%
-5.7%
Q2 2019$15,566,000
+1.2%
15,000,0000.0%0.11%
+8.2%
Q1 2019$15,385,000
+3.2%
15,000,0000.0%0.10%
-19.7%
Q4 2018$14,911,000
-5.7%
15,000,0000.0%0.12%
+17.3%
Q3 2018$15,818,000
+4.1%
15,000,0000.0%0.10%
-8.8%
Q2 2018$15,198,000
+7.8%
15,000,0000.0%0.11%
-5.0%
Q1 2018$14,099,000
-5.6%
15,000,0000.0%0.12%
-7.0%
Q4 2017$14,928,000
-1.7%
15,000,0000.0%0.13%
+4.9%
Q3 2017$15,193,00015,000,0000.12%
Other shareholders
BIOMARIN PHARMACEUTICAL INC shareholders Q3 2020
NameSharesValueWeighting ↓
SHENKMAN CAPITAL MANAGEMENT INC 30,138,000$29,510,0003.72%
PFM Health Sciences, LP 45,910,000$46,002,0001.72%
Cheyne Capital Management (UK) LLP 2,320,000$2,330,0001.47%
ADVENT CAPITAL MANAGEMENT /DE/ 41,077,000$41,277,0000.66%
SSI INVESTMENT MANAGEMENT LLC 9,071,000$9,068,0000.50%
PALISADE CAPITAL MANAGEMENT, LP 14,548,000$14,612,0000.34%
RWC Asset Management LLP 7,500,000$7,552,0000.21%
KBC Group NV 400,000$40,316,0000.15%
PROSPECTOR PARTNERS LLC 1,000,000$1,000,0000.12%
MACKAY SHIELDS LLC 11,822,000$11,816,0000.10%
View complete list of BIOMARIN PHARMACEUTICAL INC shareholders